OFORTA
LOE ApproachingNDAORALTABLET
Approved
Dec 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OFORTA is an oral small-molecule tablet approved by Sanofi in December 2008. Specific indication, mechanism of action, and pharmacologic class are not disclosed in available data. The product is classified as a New Drug Application (NDA) and remains on the market as a branded pharmaceutical.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), likely contracting team size as peak sales phase ends.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring; OFORTA is in maintenance mode. Career growth on this product is limited; professionals should expect role consolidation, transition planning, or redeployment to growth-stage brands within Sanofi's portfolio.
Brand ManagerField Sales Representative
Worked on OFORTA at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.